Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Pulmonary tuberculosis (PT) in patients taking the TNF-a inhibitor inflixinab (INF)

Pavel Gavrilov, Viacheslav Zhuravlev, Liudmila Archacova, Sergey Dolgikh
European Respiratory Journal 2011 38: p1948; DOI:
Pavel Gavrilov
1X-ray, SCT, MRT, The Reseach Institute of Phthisiopulmonology, St. Petersburg, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Viacheslav Zhuravlev
2Laboratory of Genetic Methods of Research, The Reseach Institute of Phthisiopulmonology, St. Petersburg, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liudmila Archacova
3Phthisiopulmonology, The Reseach Institute of Phthisiopulmonology, St. Petersburg, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sergey Dolgikh
4The Medical Center of Bilogical Therapy, The Medical Academy of Postgraduate Studies, St. Petersburg, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Depression of TNF-a functions by its inhibitors not only suppresses the immune-inflammatory process, but also results in certain depression of an organism immune protection level and in increase in its susceptibility to TB. The medical and X-ray date of 263 patients taking INF for treatment of rhematoid disease were analyzed. The features of PT in patients taking INF were studied. All the patients every 6 months undergo X-ray examination of the lungs. The PT has developed in 8 patients taking INF and was diagnosed in 4,6±2,5 months of therapy, the number of infusions was from 2 to 6. The PT was diagnosed after respiratory complaints, in 5 patients the MBT was isolated from the sputum. Studying of Mantoux test with 2 TE before the INF course has shown that this method does not provide any reliable information, because all the patients before that have been taking immunosuppressive hormonal therapy for a long time. The x-ray archive analysis has not resulted in identification of any pathological changes. In case of detection of the disease in 5 patients there were visible multiple changes in both lungs, it was mostly changes in the upper lobes of the lungs. 3 patients with focal dissimination had infiltrates with small destruction cavities. All the patients had typical expressed bilateral enlargement of all groups of lymph nodes, tumor type with polycyclicity of the contours. The lymph nodes structure was normal. Rapid development of PT affection is typical for all the patients with tendency to generalisation and expressed hyperplasia of intrathoracic lymph nodes. In order to determine the risk of TB before administration of INF it is necessary to carry out quantiferon test and SCT.

  • © 2011 ERS
Previous
Back to top
Vol 38 Issue Suppl 55 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Pulmonary tuberculosis (PT) in patients taking the TNF-a inhibitor inflixinab (INF)
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Pulmonary tuberculosis (PT) in patients taking the TNF-a inhibitor inflixinab (INF)
Pavel Gavrilov, Viacheslav Zhuravlev, Liudmila Archacova, Sergey Dolgikh
European Respiratory Journal Sep 2011, 38 (Suppl 55) p1948;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Pulmonary tuberculosis (PT) in patients taking the TNF-a inhibitor inflixinab (INF)
Pavel Gavrilov, Viacheslav Zhuravlev, Liudmila Archacova, Sergey Dolgikh
European Respiratory Journal Sep 2011, 38 (Suppl 55) p1948;
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • QuantiFERON-TB GOLD vs. TST methods of detection tuberculosis infection in rheumatoid arthritis patients with previously TNF α inhibitors treatment
  • Tumor nekrozis faktor-alfa blockers and tuberculosis – Analysis of the 6 years
Show more 242. Tuberculosis in immunocompromised hosts

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society